Global Infectious Diseases Diagnosis Market

Market Scope:

The global Infectious Diseases Diagnosis market is projected to grow significantly, registering a CAGR of 8.1% during the forecast period (2024 – 2032).

The diagnosis of infectious diseases involves identifying and confirming the presence of infectious agents or pathogens in individuals displaying signs or symptoms of infection. This process employs a range of techniques and methods to ascertain the root cause of the illness, enabling the implementation of suitable treatment and preventive measures. Infectious diseases, arising from bacteria, viruses, fungi, parasites, or other microorganisms, necessitate precise diagnosis for the effective management and control of the condition.
Market Overview:
Driver: Increasing demand for nucleic acid therapeutics applications to treat chronic and genetic diseases is driving the market growth.

Surging Demand for Applications of Nucleic Acid Therapeutics in Addressing Chronic and Genetic Diseases: The increasing incidence of genetic disorders such as cystic fibrosis, Duchenne muscular dystrophy, and sickle cell anemia has created a significant demand for nucleic acid-based therapies. These therapies offer the potential to treat the underlying genetic causes of these diseases, providing hope for patients who previously had limited treatment options.

Opportunities: Continued research and development activities for manufacturing innovative nucleic acid therapeutics are expected to pave the way for market growth in the upcoming years.

Ongoing Research and Development Initiatives Drive Pharmaceutical Companies to Expand Operations in the Manufacturing of Innovative Nucleic Acid Therapeutics: Pharmaceutical and biotech companies are heavily investing in research and development to explore new applications of nucleic acid-based therapies, such as mRNA, siRNA, antisense oligonucleotides, and gene editing technologies. These efforts are leading to promising clinical outcomes across a range of diseases, from rare genetic disorders to cancer and cardiovascular conditions.
Covid Impact:
The market for diagnostic tools related to infectious illnesses experienced significant impacts due to the COVID-19 pandemic. The market saw advantages arising from the elevated infection rates observed among COVID-19 patients. For instance, in February 2022, Mylab Discovery Solutions launched CoviSwift, a point-of-care (POC) RT-PCR testing system designed for use in small labs, in-hospital labs, airports, and communities. Additionally, in March 2020, BioMedomics introduced a point-of-care COVID-19 test capable of detecting antibodies in blood within 15 minutes. Moreover, in March 2020, Abbott introduced the RealTime SARS-CoV-2 assay, a PCR-based test for diagnosing COVID-19. The escalating incidence of the coronavirus heightened the demand for diagnostic tools for infectious diseases during the pandemic. Additionally, the opening of numerous diagnostic labs and testing facilities expanded the market's potential. For example, in June 2020, the Union Minister of Health and Family Welfare introduced India's first mobile I-Lab (Infectious disease diagnostic lab) for COVID-19 testing.
Segmentation Analysis:
The Human Immunodeficiency Virus (HIV) is anticipated to grow significantly during the forecast period.

The segment related to the human immunodeficiency virus (HIV) is expected to experience substantial growth throughout the study's forecast period. According to data from the Minority of HIV/AIDS Fund (MHAF) within the United States Department of Health and Human Services, last updated in June 2021, an estimated 37.6 million people were living with HIV globally in 2020, with 35.9 million being adults and 1.7 million being children under the age of 15. The same source suggests that approximately 1.5 million people contracted HIV worldwide in 2020. The market is witnessing expansion due to the increasing prevalence of HIV, leading to a growing demand for diagnostic tests and detection. Furthermore, in August 2021, the Human Rights Campaign (HRC) Foundation, in collaboration with ""Us Helping Us,"" initiated the first in-home HIV testing program for U.S. residents. The anticipation is that heightened awareness about HIV and the implementation of various initiatives by organizations globally will contribute to market growth during the forecast period.

The market's further expansion is expected to be driven by new research and developments, technological advancements, and the introduction of technologically enhanced products by key competitors. For example, in April 2021, Altona Diagnostics One launched an in-vitro diagnostic test designed to identify and quantify the human immunodeficiency virus (HIV) specific RNA in human plasma. Utilizing real-time RT-PCR technology, the test is known as the 1.5 AltoStar HIV RT-PCR Kit.

The reagents is anticipated to grow significantly during the forecast period.

The dominant influence in the infectious disease diagnostics market has been asserted by the reagents, kits, and consumables segment, primarily owing to its indispensable role in facilitating diagnostic procedures. These components play a pivotal role in diagnostic tests, enabling precise detection and characterization of pathogens. The segment has witnessed robust growth due to a steady demand for diagnostic assays. The critical significance of standardized reagents, user-friendly kits, and dependable consumables is underscored by their role in ensuring consistent and reproducible results.
Regional Analysis:
The North American region is set to witness significant growth during the forecast period.

North America is poised to secure a significant market share, driven by key factors such as the increasing prevalence of infectious diseases, substantial healthcare expenditure, and heightened awareness among the population regarding the availability of diagnostic devices. For example, the Centers for Disease Control and Prevention (CDC) reported that the 2021 flu season in the United States resulted in 9 million illnesses, 4 million medical visits, and 10,000 hospitalizations. The projected market growth in the coming years is expected to benefit from the growing burden of diseases. Moreover, in June 2021, the FDA registered Dipanjan Pan's laboratory at the University of Maryland School of Medicine (UMSOM) as an approved laboratory development site for RNA Disease Diagnostics Inc.'s Antisense COVID-19 molecular diagnostic test. Given these considerations, the market is anticipated to experience significant expansion in the region during the forecast period.

Furthermore, strategic initiatives such as collaborations, acquisitions, grant programs, and others will contribute to market expansion in the region. For instance, in July 2021, Omega Specialty Nurses (OSN), House of Sophrosyne, and the Viral Hepatitis Care Network in Ontario received grants from the 2021 CONNECT-C Grant Program from Gilead Sciences Canada, Inc. This initiative aims to expand the number of hepatitis screening centers across the nation, enhancing disease diagnosis and product adaptability, thereby driving market growth.
Competitive Analysis:
The global Infectious Diseases Diagnosis market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.

F. Hoffmann-La Roche Ltd.

• In July 2022, F. Hoffmann-La Roche Ltd introduced the Elecsys HCV Duo, a novel dual antigen and antibody diagnostic test for hepatitis C. This innovative immunoassay test represents one of the initial commercially accessible tests that enable the simultaneous and independent determination of the hepatitis C virus strain using a single human plasma or serum sample.

Abbott

bioMérieux

Siemens Healthineers AG

Danaher

Johnson and Johnson Private Limited

Cepheid

Qiagen

OraSure Technologies, Inc.
Scope of the Report
By Product & Service

• Reagents
• Kits

By Test Type

• Lab
• PoC

By Technology

• Immunodiagnostics
• NGS
• PCR
• ISH
• INAAT

By Diseases

• Hepatitis
• HIV
• HAI
• HPV
• Syphilis
• TB
• Flu

By Region

• North America (the United States & Canada)
• Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
• Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
• Rest of the World (the Middle East & Africa, and Latin America)

Key reason to purchase this report

It provides a technological development map over time to understand the industry’s growth rate and indicates how the Infectious Diseases Diagnosis market is evolving.

The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Infectious Diseases Diagnosis submarket will be the main driver of the overall market from 2024 to 2032.

It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.

It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032. Show more